Results 41 to 50 of about 89,537 (296)
Annals of MedicineBackground Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges.
Shuai Tan +4 more
doaj +1 more source
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
, 2013 Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected ...
Cutolo M +3 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source
Treatment Strategies Used in Treating Myelofibrosis: State of the Art
Hematology ReportsBackground: Current drug therapy for myelofibrosis does not alter the natural course of the disease or prolong survival, and allogeneic stem cell transplantation is the only curative treatment modality. For over a decade, the Janus kinase (JAK) inhibitor
Massimo Martino +13 more
doaj +1 more source
Vascular synovial phenotype indicates poor response to JAK inhibitors in rheumatoid arthritis patients: a pilot study [PDF]
PeerJObjective Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, characterized by significant individual variations in treatment response. Predicting treatment response remains a formidable challenge.
Mengxia Liu +4 more
doaj +2 more sources
EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
Научно-практическая ревматология, 2020 Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying anti-rheumatic drug (DMARD) tofacitinib (TOFA; Yakvinus®) in patients with active psoriatic arthritis (PsA) at 12 and 24 weeks after starting treatment ...
E. Yu. Loginova +4 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu +8 more
wiley +1 more source
Effect of JAK-STAT inhibitor on the IFN-λ3 actions.
, 2013 A. Effect of JAK-STAT inhibitor on the anti-HIV action of IFN-λ3. Macrophages were infected with HIV Bal strain for 4 days, and then incubated with JAK inhibitor I (1 µM) for 1 h prior to IFN-λ3 (100 ng/ml) treatment.
Man-Qing Liu (324762) +7 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm +11 more
wiley +1 more source
Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease:An International, Multicenter, Retrospective Cohort Study [PDF]
Background & Aims: JAK inhibitor–associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in patients with inflammatory bowel
?, ?
core +2 more sources